Table 1.
Clinical characteristics of the patients during sample collection.
| Groups |
P value | |||||
|---|---|---|---|---|---|---|
| Placebo (n = 9) | CPC + Zn (n = 7) | HP (n = 7) | CHX (n = 8) | HP + CHX (n = 12) | ||
| Male–n (%) | 6 (66.7) | 5 (71.4) | 4 (57.1) | 7 (87.5) | 10 (83.3) | 0.620 |
| Female–n (%) | 3 (33.3) | 2 (28.6) | 3 (42.9) | 1 (12.5) | 2 (16.7) | |
| Age - median (range) | 59 (36–85) | 46 (34–88) | 62 (40–87) | 53.5 (49–88) | 53 (40–72) | 0.564 |
| Number of risk comorbidities - median (range) | 1 (0–4) | 2 (0–3) | 1 (0–5) | 1 (0–4) | 1 (0–3) | 0.629 |
| Hypertension–n (%) | 2 (22.2) | 3 (42.9) | 3 (42.9) | 2 (25.0) | 3 (25.0) | |
| Heart/circulatory diseases–n (%) | 3 (33.3) | 1 (14.3) | 1 (14.3) | 2 (25.0) | 1 (8.3) | |
| Diabetes–n (%) | 2 (22.2) | 3 (42.9) | 3 (42.9) | 1 (12.5) | 1 (8.3) | |
| Lung/respiratory diseases–n (%) | 1 (11.1) | 0 (0.0) | 1 (14.3) | 1 (12.5) | 2 (16.7) | |
| Renal disease–n (%) | 0 (0.0) | 2 (28.6) | 1 (14.3) | 2 (25.0) | 0 (0.0) | |
| Obesity–n (%) | 2 (22.2) | 2 (28.6) | 0 (0.0) | 0 (0.0) | 2 (16.7) | |
| Hypothyroidism–n (%) | 1 (11.1) | 0 (0.0) | 1 (14.3) | 0 (0.0) | 2 (16.7) | |
| COVID-19 related symptoms–n (%) | ||||||
| Fatigue | 9 (100.0) | 6 (85.7) | 7 (100.0) | 7 (87.5) | 11 (91.7) | |
| Fever >37.5 °C | 6 (66.7) | 7 (100.0) | 4 (57.1) | 5 (62.5) | 7 (58.3) | |
| Headache | 3 (33.3) | 4 (57.1) | 2 (28.6) | 2 (25.0) | 6 (50.0) | |
| Cough | 7 (77.8) | 5 (71.4) | 4 (57.1) | 5 (62.5) | 12 (100.0) | |
| Diarrhea | 2 (22.2) | 3 (42.9) | 2 (28.6) | 2 (25.0) | 1 (8.3) | |
| Nasal congestion | 3 (33.3) | 7 (100.0) | 7 (100.0) | 6 (75.0) | 10 (83.3) | |
| Taste changes | 1 (11.1) | 3 (42.9) | 3 (42.9) | 1 (12.5) | 5 (41.7) | |
| Xerostomia | 7 (77.8) | 3 (42.9) | 4 (57.1) | 4 (50.0) | 5 (41.7) | |
| Dyspnea | 3 (33.3) | 7 (100.0) | 4 (57.1) | 6 (75.0) | 10 (83.3) | |
| Days of symptoms onset–median (range) | 4 (2–10) | 2 (1–6) | 7 (2–11) | 4.5 (3–10) | 5.5 (2–15) | 0.274 |
| O2saturation (%)–median (range) | 95 (92–99) | 96 (88–99) | 94 (91–97) | 96 (92–99) | 92 (90–96) | 0.563 |
| Extension of lung lesion (%)–n (%) | ||||||
| <25% | 4 (44.4) | 2 (28.6) | 2 (28.6) | 5 (62.5) | 4 (33.3) | 0.600 |
| 25%–50% | 5 (55.6) | 5 (71.4) | 5 (71.4) | 3 (37.5) | 8 (66.7) | |
HP = hydrogen peroxide; CHX = chlorhexidine gluconate; CPC + Zn = cetylpyridinium chloride, Zinc lactate.
P-values calculated using the χ2 test for categorical data and the ANOVA test for continuous data.